Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

MP Speaks Out Over Libel Threat To Scientific Debate
The MP Evan Harris is among a group of leading academics, publishers, journalists, performers, clinicians, and scientists backing science writer Simon Singh in his application to appeal against a libel judgment in the High Court today.

MorphoSys Reports Filing For Phase 1b/2a Trial For Its Lead Program MOR103 In Rheumatoid Arthritis
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the Company has submitted an application for the authorization of a phase 1b/2a clinical study in patients with active rheumatoid arthritis (RA) for its lead drug MOR103, a fully human HuCAL-derived monoclonal antibody directed against Granulocyte Macrophage-Colony Stimulating Factor. The trial, which will be conducted in multiple centers in several European countries, is expected to enroll 135 patients in total beginning in the second half of 2009. Additionally, the Company today reported positive results from the phase 1 clinical study for MOR103 in healthy volunteers. The results of this study indicate that MOR103 is generally safe and well tolerated at all doses administered.
News of the day
Major Liberal Groups Will Back Obama On Health Reform
Several of the country"s largest liberal groups said they were prepared to spend $82 million to promote President Obama"s health care reform agenda, the Boston Globe reports. "Joining the effort are two major labor organizations, the AFL-CIO and Change to Win; Health Care for America Now, a coalition of healthcare providers, consumer groups, and activists; MoveOn.org, the massive online activist organization; and other groups that claim a total of 30 million members."
Diagnostics

2009/044 NICE Guidance Recommends Tenofovir Disoproxil For Hepatitis B

The National Institute for Health and Clinical Excellence (NICE) has today (22 July) published final guidance recommending the use of tenofovir disoproxil for the treatment of people with chronic HBeAg-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated. This guidance does not apply to people with chronic hepatitis B who also have hepatitis C, hepatitis D or HIV. Dr Gillian Leng, NICE Deputy Chief Executive said: "Hepatitis B is a virus that spreads through the blood and bodily fluids of an infected person. It can be passed from person to person through activities such as unprotected sex or by sharing needles to inject drugs. Infected mothers can also transmit the virus to their baby during childbirth. One hundred times more infectious than HIV, Hepatitis B can have a serious impact on a person"s quality of life, and those with the disease are more likely to develop serious liver problems such as cirrhosis and cancer. This guidance means that patients with the virus will have another treatment option available to combat the problem of viral resistance to other drug therapies." NICE


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009